<p>Section 1: Drug discovery techniques and Strategies<br>1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery<br>2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application<br>3. Hit Discovery from DNA-Encoded Chemical Libraries<br>4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy<br>5. Macrocyclization strategy in kinase drug discovery<br>6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules<br>7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments<br>8. A future battle, small molecule drugs for cancer stem cell targeted therapy<br>9. Stem cell therapies for combating emerging and re-emerging viral infections<br>10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases<br>11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?<br>12. Selenium and small molecules: a symbiotic partnership<br>13. Novel Combinations of CD33-Targeted Immunotherapies<br>14. Novel payloads of antibody–drug conjugates<br>15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines<br>16. mRNA Vaccines: The Next Frontier in Disease Prevention<br>17. Unravelling the drying techniques of protein biopharmaceuticals<br><br>Section 2: Drug discovery case studies<br>18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections<br>19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19<br>20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer<br>21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer<br>22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer<br>23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community<br>24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia<br>25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia<br>26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor<br>27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy<br>28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure<br>29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis<br>30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic<br>31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis<br>32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin<br>33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators<br>34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis<br>35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease</p>
